Evidence
Aliment Pharmacol Ther. 2024 May;59(10):1294-1295. doi: 10.1111/apt.17992.
NO ABSTRACT
PMID:38652769 | DOI:10.1111/apt.17992
Estimated reading time: 1 minute(s)
Latest: Psychiatryai.com #RAISR4D Evidence
Cool Evidence: Engaging Young People and Students in Real-World Evidence
Real-Time Evidence Search [Psychiatry]
AI Research
Editorial: Crystalising the burden of steatotic liver disease-Authors’ reply
🌐 90 Days
AI Virtual Reality Related Evidence Matrix
- Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease
- Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease
- Review article: Hepatic steatosis and its associations with acute and chronic liver diseases
- Global perspective on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis - prevalence, clinical impact, economic implications and management strategies
- Outcomes of patients with alcohol-associated hepatitis and acute kidney injury - Results from the HRS Harmony Consortium
- A Comparison of Effectiveness of Attention Process Training (APT) with Parenting Management Training (PMT) in Reducing Symptoms of Attention Deficit Hyperactivity Disorder
- Modeling resilience to sleep disruption to study resistance to Alzheimer's disease
- The burden of non-alcoholic fatty liver disease in Australia: an analysis of Global Burden of Disease study from 1990 to 2019
- Reply to: Frailty and ethics at the end of life: The importance of a comprehensive assessment
- Outcome prediction in metabolic dysfunction-associated steatotic liver disease using stain-free digital pathological assessment
- Reduced risk tolerance and cortical excitability following COVID-19 infection
- Reduced risk tolerance and cortical excitability following COVID-19 infection
- Editorial Perspective: Extending IPDMA methodology to drive treatment personalisation in child mental health
- Persons with metabolic dysfunction-associated steatotic liver disease are at increased risk of severe depression
- Natural product pharmacology: the British Journal of Pharmacology perspective
- Metabolic dysfunction-associated steatotic liver disease prevalence and risk factors in inflammatory bowel disease in tertiary center
- Combination of risk alleles of PNPLA3, TM6SF2, and HSD17B13 of donors can predict recurrence of steatotic liver disease after liver transplantation
- Reply to: "From NAFLD to MASLD: Promise and pitfalls of a new definition": EASL, AASLD and ALEH stand united to advance the field of steatotic liver disease
- Editorial: "What say you?" The promise and potential pitfalls of using automated and passive monitoring approaches to assess parenting behaviours from verbal and written communication
- Editorial: "What say you?" The promise and potential pitfalls of using automated and passive monitoring approaches to assess parenting behaviours from verbal and written communication
- Long-term effects of ipragliflozin and pioglitazone on metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: 5 year observational follow-up of a randomized, 24 week, active-controlled trial: Effect of…
- New nomenclature for fatty liver disease
- The synergistic impact of type 2 diabetes and MASLD on cardiovascular, liver, diabetes-related and cancer outcomes
- The synergistic impact of type 2 diabetes and MASLD on cardiovascular, liver, diabetes-related and cancer outcomes
- The synergistic impact of type 2 diabetes and MASLD on cardiovascular, liver, diabetes-related and cancer outcomes
- Immunological mechanisms in steatotic liver diseases: An overview and clinical perspectives
- Swept up in the tsunami: Pediatric and adolescent steatotic (fatty) liver disease
- Metabolic-associated fatty liver disease is less effective in predicting mortality than non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
- The Transition in Terminology: From Non-alcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) to Metabolic-associated Steatotic Liver Disease (MASLD)
- Obituary: Kypros Kypri
- E-cigarette policies in Aotearoa (New Zealand): An Indigenous perspective
- Harnessing AI as an enabler for access to mental health care services
- Addiction Lives: Maggie Brady
- Stakeholders cannot simply wait for the gambling evidence-base to develop: We must all help to build it
- Assisted bathing of older adults with dementia
- Mitigating firearm risks in older adults with delirium through preventive measures
- Mitigating firearm risks in older adults with delirium through preventive measures
- Why does problem gambling in psychotic disorders pose such a challenge for comprehension?
- Contingency management as a maintenance intervention in the long-term treatment of substance use disorders
- In memoriam: Roger Guillemin, neuroendocrinologist, Nobel Prize in physiology or medicine
- The relationship between alcohol use disorder and suicide by means: Context dependent
- Physiology is all about interactions: The prolactin and growth hormone systems as exemplars
- Correction to "Peer contagion dynamics in the friendships of children with ADHD"
- Should we combine antipsychotics in patients with bipolar disorder?
- How far have we advanced in early intervention for bipolar disorder?
- ADHD medications for cognitive impairment in bipolar disorders
- Need for further exploring at the intersection of ADHD medications and bipolar disorder
- Cognitive outcomes of children and adults with sickle cell anaemia: A contemporary cohort
- Telemedicine experience among family caregivers of persons with dementia
- Commentary on Zendle and Newall: The need for direct evaluation of the UK's gambling affordability checks policy
- Beyond the microscope: Unveiling bacterial vaginosis with AI-powered multiomics data analysis
- Children with elevated wheat IgG4 antibody titer in autism spectrum disorder: Clinical presentation and findings associated with gut microbiota
- Children with elevated wheat IgG4 antibody titer in autism spectrum disorder: Clinical presentation and findings associated with gut microbiota
- Association between the skeletal muscle mass to visceral fat area ratio and metabolic dysfunction-associated fatty liver disease: A cross-sectional study of NHANES 2017-2018
- Introduction to Progress and Puzzles of Cognitive Science: Introduction to a Wiley Virtual Issue
- Letter to the Editor concerning "Electroconvulsive therapy in the maintenance phase of psychotic unipolar depression"
- Menopause and bipolar disorder: Bridging research gaps and exploring postmenopause
- Artificial dermatitis versus artificial intelligence: Detecting etiology with Google Lens
- Navigating the digital age: The need for online-specific gambling marketing regulations
- Navigating the digital age: The need for online-specific gambling marketing regulations
- Commentary on Ussher et al.: Duration and magnitude of postpartum financial incentives for the maintenance of cigarette smoking abstinence
- Community testing practices prompt the rethinking of gold standard autism assessment
- Experiences of children and adolescents with attention-deficit/hyperactivity disorder taking methylphenidate
- Reflecting on the association between video game addiction and early-stage inhibitory control issues: Insights from Taiwan
Evidence Blueprint
Editorial: Crystalising the burden of steatotic liver disease-Authors’ reply
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Editorial: Crystalising the burden of steatotic liver disease-Authors’ reply
🌐 365 Days
AI Virtual Reality Related Evidence Matrix
- Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease
- Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease
- Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease
- Psychedelics in treatment of postraumatic stress disorder
- Prevalence of at-risk MASH, MetALD and alcohol-associated steatotic liver disease in the general population
- Review article: Hepatic steatosis and its associations with acute and chronic liver diseases
- The silent burden of non-alcoholic fatty liver disease in the elderly: A global burden of disease analysis
- Global perspective on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis - prevalence, clinical impact, economic implications and management strategies
- Review article: Current indications and selection criteria for early liver transplantation in severe alcohol-associated hepatitis
- Meta-analysis: Impact of intragastric balloon therapy on NAFLD-related parameters in patients with obesity
- Outcomes of patients with alcohol-associated hepatitis and acute kidney injury - Results from the HRS Harmony Consortium
- Meta-analysis: Efficacy and safety of fibroblast growth factor 21 analogues for the treatment of non-alcoholic steatohepatitis and non-alcoholic steatohepatitis-related fibrosis
- Machine learning improves the prediction of significant fibrosis in Asian patients with metabolic dysfunction-associated steatotic liver disease - The Gut and Obesity in Asia (GO-ASIA) Study
- Systematic review: Glycomics as diagnostic markers for hepatocellular carcinoma
- Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis
- MAFLD fibrosis score: Using routine measures to identify advanced fibrosis in metabolic-associated fatty liver disease
- First in human randomised trial of J2H-1702: A novel 11β-hydroxysteroid dehydrogenase type 1 inhibitor for non-alcoholic steatohepatitis treatment
- MDMA-assisted therapy for PTSD
- A Comparison of Effectiveness of Attention Process Training (APT) with Parenting Management Training (PMT) in Reducing Symptoms of Attention Deficit Hyperactivity Disorder
- Modeling resilience to sleep disruption to study resistance to Alzheimer's disease
- The burden of non-alcoholic fatty liver disease in Australia: an analysis of Global Burden of Disease study from 1990 to 2019
- Associations of dietary sugars with liver stiffness in Latino adolescents with obesity differ on PNPLA3 and liver disease severity
- Reply to: Comment on: Association of sulfonylureas with the risk of dementia: A population-based cohort study
- Reply to: Frailty and ethics at the end of life: The importance of a comprehensive assessment
- Potential Mechanisms Involving in the Pathogenesis of MASLD and Targets for Pharmacotherapy. Advancements in Metabolic Associated Steatotic Liver Disease (MASLD) Research: Diagnostics, Small Molecule Developments and Future Directions
- Outcome prediction in metabolic dysfunction-associated steatotic liver disease using stain-free digital pathological assessment
- Letter regarding 'Association of thyroid function with non-alcoholic fatty liver disease in recent-onset diabetes'
- Reply to Ng: a closer look at late-onset psychoses for the general internist
- Reply to: Disease latency and new-user versus prevalent-user cohort designs: Implications for pharmacoepidemiology in dementia
- Reduced risk tolerance and cortical excitability following COVID-19 infection
- The promise of N-acetylcysteine in the treatment of obsessive-compulsive disorder
- Reduced risk tolerance and cortical excitability following COVID-19 infection
- Pharmacogenetic testing of CYP2D6, CYP2C19 and CYP2C9 in Denmark: Agreement between publicly funded genotyping tests and the subsequent phenotype classification
- A novel dual near-infrared fluorescent probe for bioimaging and visualization of viscosity in acute alcoholic liver injury
- Innovative pharmacotherapy for hepatic metabolic and chronic inflammatory diseases in China
- Relationship of ferritin and hepcidin with disease severity in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus
- Editorial: Prevention is the best cure - or is it? A cautionary tale
- MBOAT7 in liver and extrahepatic diseases
- Editorial Perspective: Extending IPDMA methodology to drive treatment personalisation in child mental health
- Steatotic liver disease is the most important somatic determinant of quality of life in patients with obesity: A cross-sectional study
- Correction to "Hepatobiliary and Pancreatic: Challenges in the diagnosis of hepatic nodules in patients with alcoholic liver cirrhosis"
- Association of liver fibrosis with extrahepatic cancer in steatotic liver disease patients with PNPLA3 I148M GG genotype
- Exclusive liquor and cocktail consumption is associated with at-risk fibrosis among nonheavy alcohol users with metabolic dysfunction-associated steatotic liver disease
- Commentary on Booth et al.: Measuring the health burden of homelessness
- Liver disease mortality and hospitalisations among people with type 2 diabetes mellitus: A population-based study
- Persons with metabolic dysfunction-associated steatotic liver disease are at increased risk of severe depression
- The double roles of T cell-mediated immune response in the progression of MASLD
- Natural product pharmacology: the British Journal of Pharmacology perspective
- Metabolic dysfunction-associated steatotic liver disease prevalence and risk factors in inflammatory bowel disease in tertiary center
- Obituary: Travis Thompson-Editorial
- Combination of risk alleles of PNPLA3, TM6SF2, and HSD17B13 of donors can predict recurrence of steatotic liver disease after liver transplantation
- Non-alcoholic fatty liver disease, women's health and the role of the environment
- Epidemiology, screening, and Co-management of type 2 diabetes mellitus and Metabolic-dysfunction associated steatotic liver disease
- Relationship between Helicobacter pylori infection and risk of metabolic dysfunction-associated steatotic liver disease: An updated meta-analysis
- Reply to: "From NAFLD to MASLD: Promise and pitfalls of a new definition": EASL, AASLD and ALEH stand united to advance the field of steatotic liver disease
- From metabolic dysfunction-associated fatty liver disease to metabolic dysfunction-associated steatotic liver disease: Controversy and consensus
- Editorial: "What say you?" The promise and potential pitfalls of using automated and passive monitoring approaches to assess parenting behaviours from verbal and written communication
- Editorial: "What say you?" The promise and potential pitfalls of using automated and passive monitoring approaches to assess parenting behaviours from verbal and written communication
- Long-term effects of ipragliflozin and pioglitazone on metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: 5 year observational follow-up of a randomized, 24 week, active-controlled trial: Effect of…
- Metabolic-Associated Steatotic Liver Disease (MASLD): A New Term for a More Appropriate Therapy in Pediatrics?
- New nomenclature for fatty liver disease
- Erythropoietin hyporesponsiveness in non-alcoholic fatty liver disease
- Therapeutic management of metabolic dysfunction associated steatotic liver disease
- Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study